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DNA adducts play a central role in chemical carcinogenesis. The analysis of formation and repair of smoking-related DNA adducts
remains particularly challenging as both smokers and nonsmokers exposed to smoke are repetitively under attack from complex
mixtures of carcinogens such as polycyclic aromatic hydrocarbons and N-nitrosamines. The bulky DNA adducts, which usually
have complex structure, are particularly important because of their biological relevance. Several known cellular DNA repair
pathways have been known to operate in human cells on speciﬁc types of bulky DNA adducts, for example, nucleotide excision
repair, base excision repair, and direct reversal involving O6-alkylguanine DNA alkyltransferase or AlkB homologs. Understanding
the mechanisms of adduct formation and repair processes is critical for the assessment of cancer risk resulting from exposure to
cigarette smoke, and ultimately for developing strategies of cancer prevention. This paper highlights the recent progress made in
the areas concerning formation and repair of bulky DNA adducts in the context of tobacco carcinogen-associated genotoxic and
carcinogenic eﬀects.
1.Introduction
Tobacco was traded from North America to the world
about 500 years ago. Since then, tobacco use by smoking
cigarettes, cigars, and pipes, or by chewing, has wreaked
havoc on mankind. Nearly 1.3 billion people are active
smokers worldwide [1], who also pose a threat of indirect
exposure to even more nonsmokers through secondhand
smoke (SHS, also known as environmental tobacco smoke,
ETS). Cigarette smoke accounts for 30% of all cancer deaths.
Based on the International Agency for Research on Cancer
(IARC),cigarette smoking is associated with cancersin many
organs/tissues such as lung, head, neck, and bladder [2].
The lung is particularly vulnerable as ∼90% of lung cancer
casesarecausedbycigarettesmoking.Cigarettesmokecauses
other diseases as well, including pulmonary disorders, car-
diovascular diseases and stroke, and developmental defects.
There is also suﬃc i e n te v i d e n c ei nr e c e n ty e a r st h a tS H S
causeslungcancer[3].InUSnonsmokers,SHSisresponsible
for about 3,000 lung cancer deaths, 46,000 cardiac-related
illnesses, and 430 sudden infant death syndrome (SIDS) per
year [4].
Four types of smoke have been classiﬁed so far [5]: (1)
Mainstream smoke (MSS), created by tobacco combustion
at approximately 1,200–1,600
◦C, when smokers inhale the
tobacco smoke from a burning cigarette, (2) Sidestream
smoke (SSS), emanating from the smouldering end of a lit
cigarette at ∼ 900
◦C when no active smoking occurs while
the smoker pauses before taking the next puﬀ, (3) SHS, a
mixture of about 85% of SSS and 15% of exhaled MSS, and
(4) Thirdhand smoke (THS), a newly emerged type, deﬁned
as residual tobacco smoke adsorbed onto indoor surfaces
after active smoking has ceased, where the semivolatile and
nonvolatile components undergo chemical transformation
to produce new toxicants [6–8].
In the last 50 years, many studies have been per-
formed to identify chemical toxicants in cigarette smoke,
which may represent the most rich resource of exogenous
human mutagens and carcinogens. MSS contains more
than 4,000 chemicals. Among them, over 60 have been
classiﬁed by IARC as carcinogens [9]. These include 10
polycyclic aromatic hydrocarbons (PAHs), 6 hydrocarbons,
10nitrosamines,13aromaticamines,2aldehydes,3phenolic
compounds, 4 volatile hydrocarbons, 3 nitro compounds,2 Journal of Nucleic Acids
12 miscellaneous organic compounds, and 9 inorganic and
metals compounds [10]. This list contains some of the
strong animal and/or human carcinogens, such as PAHs, N-
nitrosamines, and aromatic amines, all of which react with
DNA to form adducts [11–13]. The most prevalent ones
in the vapor phase are aldehydes, benzene, and butadiene.
It should be emphasized that SSS or SHS also contains
several thousand individual compounds as does MSS [5],
and most of the above-mentioned carcinogens are also
present in SSS/SHS [12]. Since such a carcinogenic source,
that is, cigarette smoke, is preventable, and DNA adduct
levels correlate with cigarette consumption [13], tobacco
smokeprovidesauniquemodelforunderstandingthecause-
eﬀect or environment-gene relationship in smoking-related
cancer development. However, the real assessment of such
relationships is very diﬃcult due to multiple reasons [14].
For example, Metabolic activation imposes an additional
levelofcomplexityforsuchassessment.Inaddition,cigarette
smoke contains co-carcinogens and tumor promoters that
are also crucial for tumorigenicity of smoke condensates
[12, 15, 16].
Although certain carcinogens in cigarette smoke, such
as formaldehyde and α,β-unsaturated aldehydes (enals),
directly react with DNA to form covalent adducts, most of
carcinogenic compounds are so-called procarcinogens that
mustbemetabolicallyactivatedtoformultimatecarcinogens
[12]. These metabolites are usually electrophilic that react
with the nucleophilic sites on DNA bases. The well-studied
microsomal cytochrome P450 (CYP) system [17]a c t i v a t e s
many tobacco carcinogens such as PAHs, N-nitrosamines,
aromatic amines, and benzene [18–20]. Therefore, carcino-
gen metabolism is often a double-edged sword in that it not
only detoxiﬁes and excretes toxicants but may also convert
them into harmful reactive species. The individual variation
in metabolic activation such as genetic polymorphisms in
carcinogen-metabolizing genes is an important determinant
of DNA adduct levels and is used to identify smokers with
increased cancer risk [21, 22].
MostchemicalcarcinogensreactwithcellularDNAasthe
ultimate target. Cigarette smoke condensates were initially
known to have mutagenic activity by the 1970s [23], and
adducts were detected in cellular DNA from smokers in the
1980s [24]. Since then, many tobacco carcinogen-derived
adducts have been identiﬁed in vitro and in vivo, owing
to the development of highly sensitive analytical detection
methods, such as 32P-postlabeling and mass spectrometry
(MS) [25, 26]. It has been shown that cigarette smokers
have higher levels of DNA adducts than nonsmokers [12, 13,
27, 28]. Studies have also shown that current smokers have
higher adduct levels compared with former smokers [13].
With some exceptions of inconsistency, many epidemiologic
and clinical studies have shown an association between
the in vivo levels of DNA adducts resulting from cigarette
smoke and the occurrence of tobacco-related cancers in
lung, head and neck, and bladder [13]. There are numerous
reviews speciﬁcally related to the relationships between
tobacco carcinogen exposure, DNA adduct formation, car-
cinogen/adduct mutagenic potential, and increased cancer
risk related to smoking [13, 19, 26, 27, 29–32].
Tobacco carcinogens generate a broad spectrum of DNA
lesions ranging from sugar damage, apurinic/apyrimidinic
(AP) sites, small modiﬁed bases (e.g., O6-mG and 8-
oxoG), and bulky base adducts to more deleterious lesions
such as DNA crosslinks and strand breaks. The so-called
bulky DNA adducts are formed by the covalent binding
of those chemical carcinogens with large size, such as
PAHs and aromatic amines, to various sites on DNA bases.
These adducts also include exocyclic DNA bases such as
the etheno, propano, and benzetheno adducts formed by
respective bifunctional compounds [33, 34]. These bulky
adducts represent a major and important class of DNA
damage originating from exposure to cigarette smoke. One
characteristic of these bulky adducts is that they tend to
signiﬁcantly disrupt the DNA helical structure and block
Watson-Crick base pairing [35, 36]. They are usually highly
mutagenic, as exempliﬁed by the PAH-DNA adducts [30]
and exocyclic DNA adducts [34, 37]. Some of them may
not be repaired (e.g., benzo[c]phenanthrene N6-dA adducts
[38]) or only poorly repaired (e.g., two dibenzo[a,l]pyrene-
induced DNA adduct [39]), thus leading to their persistence
in genomic DNA. Smokers with high levels of these bulky
adducts have been shown to be associated with an increased
risk of cancers [40, 41]. In fact, most of the compelling
data on the connection of DNA adducts with cancer have
been obtained with bulky DNA adducts and their respective
carcinogens. For example, PAH- and acrolein-DNA adducts
are preferentially formed in the same mutational hotspots
of p53 in the lung cancers of smokers [30, 42, 43]. This
tumor suppressor gene is frequently mutated in ∼40% of
lung cancer cases. There is also evidence that a high level
of bulky DNA adducts in tissues, such as those caused by
PAHsandvinylchloride(VC),isassociatedwithanincreased
risk of tumor in humans and animals [40, 44–46]. It should
be pointed out that tobacco smoke also produces reactive
oxygen species (ROS) and induces oxidative stress [11, 47].
Those lesions that arise directly from ROS attack of a base
(e.g., 8-oxoG) or deoxyribose (e.g., base propenals) [48, 49]
could also play a role in tobacco carcinogenesis.
Cigarette smoking can cause complex biological
responses.Ifunrepaired,DNAadductsmayblockreplication
andtranscription. Thereisevidencethatonlyasingle BPDE-
DNA adduct can eﬀectively block expression of a reporter
gene [50]. DNA damage can either activate checkpoint
signaling pathways leading to cell cycle arrest or induce cell
apoptosis by recruitment of immunologic and inﬂammatory
responses [31]. More importantly, persistence of DNA
adducts such as those formed by tobacco carcinogens PAHs
and N-nitrosamines plays a central role in tobacco-induced
carcinogenesis [27]. These adducts not only represent a
very early event by inducing speciﬁc genetic changes that
are a prerequisite to the initiation of cancer, but also occur
during the continuum of the carcinogenic process [31].
DNA adducts can lead to nucleotide misincorporation,
thus causing gene mutations. Mutations in the p53 gene are
more commonly observed in lung cancers from smokers
than nonsmokers [51, 52]. Exposure to smoking has been
associated with activating mutations in proto-oncogenes
(e.g., the ras gene family) and inactivation of tumorJournal of Nucleic Acids 3
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Figure 1:Schematicpresentationoftheformation,repairandmutagenicpotentialoftobaccocarcinogen-inducedbulkyadductsingenomic
DNA. The formation of a bulky DNA adduct (marked in red), if not repaired or poorly repaired, results in multiple genetic changes such
as cell death and gene mutation. TLS (translesion DNA synthesis) can prevent a mutation by error-free incorporation opposite the adduct.
Error-prone incorporation at the adduct site by replicative or translesional DNA pols is the source for mutation. Only those adducts that
ﬁnally escape all the defense mechanisms may lead to biologically important mutations.
suppressor genes (e.g., p53 and p16)i nc a n c e r s[ 53–56].
Microarray-based analyses also reveal that cigarette smoking
alters expression of many genes involved in other functions
[57]. In addition to point mutations, there are correlations
between DNA adduct levels and other somatic alterations,
for example, loss of heterozygosity (LOH) that may occur
at the very early stages of tobacco carcinogenesis [58, 59].
In addition, epigenetic changes such as abnormal promoter
methylation of certain genes also occur more frequently in
lung tumors from smokers than in never-smokers or may
appear in healthy individuals who start to smoke [60, 61],
highlighting the importance of both genetic and epigenetic
changes in tobacco carcinogenesis. Tobacco carcinogens
can also contribute to tumorigenesis by interacting with
proteins, RNA, and lipids, in addition to DNA.
To avoid tobacco carcinogen-induced DNA damage,
quitting smoking or avoiding exposure is the ﬁrst and
foremost important approach. However, once such damage
is formed, DNA repair is the next major defense mechanism
(Figure 1). Organisms from prokaryotes to mammals have
evolved a number of repair pathways, including direct
reversal, base excision repair (BER), nucleotide excision
repair (NER), mismatch repair (MMS), and double-strand
break (DSB) repair [62–64]. In model systems, such as
cultured cells and genetically manipulated organisms, these
pathways have been shown to operate on speciﬁc types of
DNA lesions. NER is the major pathway for the repair of
various duplex-distorting bulky DNA lesions such as those
induced by PAHs. Small alkylated and oxidized lesions,
including those arising from endogenous sources,are excised
by the BER pathway which also repairs certain single-ring
exocyclic DNA adducts. For certain alkylated bases and
etheno adducts, they can be repaired through direct reversal
carried out by specialized repair proteins. In general, the
understanding of damage recognition and mechanism of
repair is important to gain insight into the speciﬁc roles
of tobacco DNA adducts in the development of cancer and
other chronic diseases since, at the end, the overall cellular
repair capacity in response to exposure is critically related
to the levels of DNA adducts in the genome or mutations
in genes. The role of individual variability in repair, for
example, polymorphisms in repair genes, has been related to
the increased cancer risk in smokers [22, 65, 66]. Ultimately,
it is the impaired or poor repair of DNA adducts (e.g.,
those bulky adducts and oxidized bases with cytotoxicity and
mutagenicity) that is expected to be most important in the
etiology of smoking-related cancer and other disorders.
Studies in the last decade have revealed that if a DNA
adduct is unrepaired or irreparable, cells may use translesion
DNA synthesis (TLS) to bypass the adduct to ensure the
continuumofDNAreplication[67–69].TLSisperformedby
variousspecializedDNApolymerases(pols),mostlyfromthe
Y-family, with the possibility of nucleotide misincorporation
[70, 71]. These enzymes possess an open and preformed
active site, enabling accommodation of a broad spectrum
of DNA adducts with diﬀerent structures [69]. In studies
reported in literature, error-prone incorporations opposite
an adducted nucleotide appear to occur commonly or co-
exist with error-free incorporations [72–74]. However, in
some other cases, TLS pols perform error-free bypass on
damaged DNA templates such as the eﬃcient and correct
nucleotide incorporation at the acrolein adduct γ-HO-PdG
bypolιandsubsequentextensionofreplicationbypolκ[75].
The ﬁdelity of TLS observed in these experiments tends to
depend on the individual pol tested as well as the structure of
the target adduct. In general, the primary roles of these pols4 Journal of Nucleic Acids
and how they operate in the cell with regard to interacting
with replication and repair machineries remain to be further
understood.
This paper will focus on the formation and repair
of bulky/exocyclic DNA adducts induced by the major
tobacco carcinogens in relation to tobacco mutagenesis and
carcinogenesis. For small base lesions induced by tobacco
chemical carcinogens, see previous reviews by Singer [76]
and Shrivastav et al. [77]. In general, the literature so far
on the covered review topics has been extensive. Therefore,
onlyselectedpublisheddataareusedtoillustratetherelevant
areas, ideas, and concepts. I regret that this review does not
permit acknowledgment of the many researchers who made
the original ﬁndings in these important areas.
2. Formation andRepair of Bulky DNA
Adducts by Tobacco Carcinogens
2.1. Formation of Bulky DNA Adducts: An Overview. Since
smokers are repetitively exposed to complex mixtures of
genotoxic carcinogens, the collective formation of DNA
adducts is very complex as reﬂected by their chemical
types and cellular levels. Although this paper is focused on
bulky DNA adducts, other types of DNA lesions by tobacco
carcinogens may be equally or more important than bulky
DNA adducts for a given carcinogen or cancer type. DNA
adduct levels are normally analyzed in target tissues in order
to elucidate the relationship between tobacco carcinogens
and cancer development. These levels should reach steady
state such that the number of newly formed adducts equals
the number of adducts lost every day which are related to a
number of factors including carcinogen reactivity, exposure
doses, timing of exposure, metabolic processes, and DNA
repair capacity [13]. Understanding of DNA adducts with
regardto their formation, isolation, and identiﬁcation canbe
critical in several ways: (1) to understand the mechanism of
tobacco carcinogens; for example, the analysis of formation
of DNA adduct at gene mutational hotspots [30, 78]h a s
provided important insight into the cancer etiology; (2) to
assess the biologically eﬀective doses of tobacco carcinogens
[25]; (3) to assess DNA repair capacity (DRC) towards
the adducts [13, 79]; (4) to ﬁnd biomarkers of tobacco
genotoxicity and uptake/metabolism of speciﬁc carcinogens
[12, 13].
Many types of DNA adducts, including those formed by
benzo[a]pyrene (B[a]P), 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone (NNK), N -nitrosonornicotine (NNN),
and 4-aminobiphenyl (4-ABP), have been detected from
tissues of smokers as well as nonsmokers exposed to SHS
[11–13, 80–82]. The common tobacco carcinogens and
related metabolites that give rise to bulky DNA adducts are
listed in Figure 2. In tissues, the typical adduct levels are
at about 1 adduct in 106-107 normal bases [27, 83]. In
general, DNA adduct levels as low as 1 in 106–1012 normal
basescanbesigniﬁcantwithdeﬁnitebiologicalconsequences
[84].Although 32P-postlabelingandimmunoassayhavebeen
extensively utilized for adduct analysis, the detection and
identiﬁcation of DNA adducts at these or even lower levels
have been greatly facilitated by the highly sensitive/speciﬁc
and new types of techniques [11, 12, 25, 26]s u c ha sH P L C
with ﬂuorescence, mass spectrometry (MS), and electro-
chemical detection, particularly the coupling of liquid chro-
matography (LC) to MS and electrospray ionization (ESI),
that is, LC-ESI-MS [25]. The number of compounds/DNA
adducts in Figure 2 is expected to grow when more of such
studiesarecarriedout.ItshouldbeemphasizedthatSHSalso
contains all of the common carcinogenic compounds listed
in Figure 2, albeit with varying concentrations. Some of the
signiﬁcantly existing chemical carcinogens in SHS are NNK,
NNN, B[a]P, benz(a)anthracene, benzene, 1,3-butadiene, 4-
ABP, and 2-napthylamine [5].
In addition to being directly formed by tobacco carcino-
gens, DNA adducts can be generated through inﬂammation,
particularlybyROSandreactivenitrogenspecies(RNS).Due
to the direct surface exposure, cigarette smoking triggers an
inﬂammatory response in human lung and causes chronic
obstructivepulmonarydisease(COPD)[85],whichhasbeen
shown to possess signiﬁcant abnormalities in inﬂammatory
pathways [86–89]. Smokers are known to have elevated levels
of oxidative stress [11, 47], which is increasingly linked to
cancer and neurological diseases [90, 91]. Cigarette smoke
may induce oxidative stress by several mechanisms [11, 47]:
(1) it contains oxidizing compounds and ROS; (2) the ROS-
generating redox cycling by quinone-hydroquinone complex
as well as PAH quinones and their corresponding catechols;
(3) smoking may weaken the antioxidant defense system.
The elevated oxidative stress in smokers is accompanied by
lipid peroxidation (LPO) [11] which results from reactions
of reduced oxygen species with polyunsaturated fatty acids
(PUFAs). It is well documented that LPO produces enals,
including acrolein, crotonaldehyde, and trans-4-hydroxy-2-
nonenal (HNE) [92–94]. These compounds react with DNA
to produce etheno (ε) - a d d u c t sa sw e l la sp r o p a n oa d d u c t s
[92–94]. This explains why chronic inﬂammation in humans
is accomplished by increased levels of such adducts [94].
It should be noted that these adducts are also present in
tissues of humans and untreated animals at very low levels
as background lesions [92–94].
To understand the chemistry between a carcinogen
and DNA bases is instrumental in revealing the molecular
mechanism of mutagenicity and carcinogenicity of the
carcinogen [18]. A single carcinogen can cause several
diﬀerent types of DNA damage, mainly due to the process
of metabolism that can yield several or many reactive
metabolites. All the carcinogens listed in Figure 2 can form
more than one type of DNA adducts. For example, NNK
can form both simple methylated and bulky pyridyloxobutyl
(POB) adducts [80, 84]. A single electrophilic carcinogen
can form multiple adducts of the same nature by reacting
with all four DNA bases. For example, benzene metabolites,
hydroquinone (HQ) and para-benzoquinone (p-BQ), form
exocyclic adducts on dA, dC, and dG [95–98]. BPDE,
by way of another example, can generate both dG and
dA adducts. Diﬀerent carcinogens preferentially react with
diﬀerentsitesonthebases[18].FordG,PAHspredominantly
bind to its 2-NH2 group, alkylating agents such as tobacco-
speciﬁc nitrosamines (TSNAs) mainly react at the N-7 or O6
position, and aromatic amines tend to bind to the 8-carbonJournal of Nucleic Acids 5
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position [25]. All oxygen and nitrogen sites on DNA bases
are actually reactive with alkylating agents in vitro under
physiological conditions [18].
Of the DNA adducts formed by tobacco carcinogens,
exocyclic adducts have been extensively studied for their
chemistry of formation [34, 99]. Bifunctional electrophilic
compounds such as HQ and p-BQ, acrolein, and VC
metabolites, are all able to form exocyclic adducts [44]. The
common sites for forming an exocyclic ring are N-1 and N6
of dA, N-3 and N4 of dC, N-1 and N2 of dG as well as N2
and N-3 of dG (superscript indicates exocyclic oxygen or
nitrogen) [100]. Adducts may be promutagenic if formed at
coding sites of the bases, including O6, N-1, and N2 of dG,
N-1 and N6 of dA, O2, N-3, and N4 of dC, and O4 and N-
3o fT[ 101]. Structurally, exocyclic adducts are analogous
but can diﬀer in ring structure such as size (e.g., 5- versus
6-membered), number (e.g., one ring versus two rings),
angularity (e.g., linear versus angular), substituents’ nature
(e.g., –OH versus –CH2OH), and location (e.g., α-HO-
PdG versus γ-HO-PdG) [34, 102]. The structural features of
speciﬁc adducts may deﬁne the speciﬁcity and eﬃciency of
their repair, as discussed below, as well as their mutagenicity.
2.2. Repair of Bulky DNA Adducts: An Overview. In the last
two decades or so, considerable progress has been made
in understanding the speciﬁcity, mechanism of action, and
in vivo importance of many repair enzymes and pathways.
This has been greatly facilitated by major advances in dis-
covery of new enzymes or novel activities, synthesis of site-
directed damage-containing oligonucleotides, construction
of damage-containing shuttle vectors and viral genomes for
in vivo studies, determination of high-resolution structures
of repair enzymes and damaged DNA, development of
gene mutant models, identiﬁcation of protein interaction
networks,geneanalysessuchasmutationspectrummapping
and single nucleotide polymorphisms (SNPs), and by the
latest studies using omic proﬁling technology. There are
many excellent reviews speciﬁcally related to the complete
p r o c e s sa sw e l la ss p e c i ﬁ cr e p a i rp a t h w a y st h a tr e s t o r eD N A
to its normal state [62–64, 103–108].
Several major mechanisms have been shown to be
involved in the repair of bulky DNA adducts that can be
induced by tobacco carcinogens, as discussed below in detail.
It is important to determine which adducts are removed
eﬃciently or poorly, as those adducts that persist may cause
a greater long-term mutagenic potential. Excision repair,
whether it is base (BER) or nucleotide excision (NER),
has to be at least a two-step process in which the damage
recognition and excision is followed by DNA replication,
whereas direct reversal, catalyzed by O6-alkylguanine DNA
alkyltransferase (AGT, also known as MGMT) or AlkB
homologs (ABHs), restores the normal base without excision
[64]. Multiple repair mechanisms could be involved in the
removal of various DNA adducts produced by a single
compound. As will be described below, the benzetheno
adducts of HQ/p- B Qa r es u b s t r a t e sf o rA Pe n d o n u c l e a s e ,
and the hydroxyphenyl dG adduct formed by the same
compounds is repaired by NER. In some cases, more than
one enzyme or mechanism can act on the same adduct,
which may serve as backups or operate with diﬀerent
functions in the cell.For example, 3, N4-ethenocytosine (εC)
is excised by three diﬀerent DNA glycosylases and repaired
by two diﬀerent repair pathways, BER and ABH2. Although
the mismatch repair (MMR) pathway appears not to be
directly implicated yet as signiﬁcantly as the above pathways
in response to the bulky adducts, MutS protein has been
shown to bind to the propano dG and M1G adducts [109],
suggesting that MutS can bind to exocyclic adducts and may
trigger a MMR-mediated response.
Although certain repair data come from research using
prokaryotic enzymes, this paper will concentrate on mam-
malian/human repair enzymes whenever possible. In prin-
ciple, the analogous enzymes and general mechanisms exist
in both prokaryotes and eukaryotes, and such conservation
has provided a solid foundation for our understanding of
mammalian repair. It should also be pointed out that much
of the repair data concerning tobacco carcinogen-derived
adducts was not directly obtained from tobacco-related
studies, but rather based on reports focusing on chemical
carcinogens per se.
2.3. Repair of Speciﬁc DNA Adducts by Diﬀerent Pathways
2.3.1. Nucleotide Excision Repair (NER). NER is the
most versatile repair pathway in the cell and the primary
mechanism for the removal of chemical carcinogen-induced
bulky DNA adducts that signiﬁcantly distort the DNA helix
structure [64, 107, 110, 111]. The molecular mechanism
of NER is now well understood. Its pathway in eukaryotes
consists of at least 30 gene products [112]a n dc a nb e
reconstituted with puriﬁed key proteins in vitro [113, 114].
Mutations in some of these NER genes may lead to
xeroderma pigmentosum (XP), a genetic disorder with seven
complementation groups (from XPA to XPG), and a higher
incidence of skin cancer [64]. The steps in NER consist
of sequential assembly of proteins that perform diﬀerent
functions: damage recognition by XPC-HR23B, opening of
a denaturation bubble by TFIIH, incision of the damaged
strand by XPG and ERCC1-XPF, displacement and excision
of the lesion-containing oligonucleotide (24–32 base long),
repair synthesis by DNA polymerase δ/ε, and DNA ligation
by ligase III. There are two subsets of the pathway: global
genomic repair (GGR) and transcription-coupled repair
(TCR) that diﬀer in the mode of damage recognition and
are regulated by diﬀerential cellular mechanisms [105,
107, 110, 111]. GGR is involved in repair of DNA lesions
from the transcriptionally silent regions of the genome
and the nontranscribed strand of the active genes. GGR
probes for DNA lesions that cause structural distortion or
chemical alteration. TCR preferentially repairs the distorting
lesions on the transcribed strand in active genes in order to
a v o i das t a l l e dR N Ap o l y m e r a s eI I .T h em a m m a l i a nN E R
activity appears to be mostly modulated by posttranslational
modiﬁcations and by protein-protein interactions.
NER activity can be measured in cell-free extracts by
the cleavage of site-directed oligonucleotide containing an
adduct or by the extent of DNA repair synthesis in damaged
plasmid DNA. Figure 3 shows the structures of importantJournal of Nucleic Acids 7
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Figure 3: Structures of smoking-induced bulky DNA adducts that are substrates for NER.
toxic and mutagenic bulky adducts as NER substrates
which are formed by those major carcinogens in cigarette
smoke, including PAHs, acrolein, 4-ABP, and benzene. NER
also processes endogenous bulky DNA adducts formed by
enals from LPO [115]. In addition, intra- and interstrand
crosslinks such as those generated by UV light and cisplatin
are usually repaired by NER [64]. These crosslinks could
also be formed by bifunctional tobacco chemicals such as
acrolein and crotonaldehyde [116]. Therefore, NER is a
critical repair pathway for protecting against the tobacco
carcinogen-induced mutagenesis and carcinogenesis.
(1) Formation and Repair of PAH-Derived DNA Adducts.
PAHs are thought to be the major contributors to the
etiology of smoke-induced cancers, particularly lung cancer.
B[a]P was the ﬁrst carcinogen to be found in cigarette
smoke [117] and has been extensively studied as a sur-
rogate for PAHs. It is present in cigarette smoke at low
levels (10–50ng/cigarette) but is higher than other PAHs
[11]. In one well studied metabolic pathway mediated
by successive P450/epoxide hydrolase/P450, B[a]P yields
active carcinogenic epoxides, mainly B[a]P-7,8-diol-9,10-
epoxide (BPDE) [18, 118]. The diol epoxide exists as two
diastereoisomers, anti-a n dsyn-BPDE, each of which can be
resolved into (+)- and (−)-enantiomers. The isomer (+)-
anti-BPDE has the greatest tumorigenicity in vivo [119]. The
latter reacts at the N2 of dG to yield either trans-o rcis-ring
opening of the epoxide ring, forming (+)-trans- and (+)-
cis-BPDE-N2-dG adducts [120, 121]. Similarly, (−)-anti-
BPDE forms (−)-trans-a n d( −)-cis-BPDE-N2-dG adducts.
Of these four stereoisomeric adducts, (+)-trans-BPDE-N2-
dG is the most abundant, which is also the major adduct
identiﬁed in vivo [122, 123] and was detected in 45%
of smokers’ lung [124]. A second path for the activation
of B[a]P involves P450-mediated activation to yield free
cations [125] that can induce unstable adducts leading to
AP sites. A third metabolic pathway is through aldo-keto
reductase superfamily-mediated oxidation of B[a]P-7,8-diol
to catechol that enters into a redox cycle to form a reactive
B[a]P-7,8-quinone (BPQ) [126, 127]. Although a recent
study did not support that BPQ forms stable DNA adducts
in mice [128], there is evidence that this pathway operates in
human lungs leading to ROS-mediated genotoxicity such as
causing G to T transversions that inactivate p53 [127, 129].
So far, the relative importance of these pathways in cancer
development remains to be determined.
BPDE-DNA adducts are recognized and repaired by E.
coli NER complex UvrABC nuclease [130] and human NER
[131–133]. Taking advantage of the stereochemistry involved
in the formation of these bulky adducts, a number of studies
addressed the eﬀects of adduct conformation, base paring,
and sequence context on DNA repair. For example, using an
in vitro repair system with oligonucleotides containing one
of the four BPDE-N2-dG adducts described above Hess et al.
showed that the rates of human NER repair of these adducts
are dependent on their diﬀerent stereochemical conﬁgura-
tions [131]. The rates of excision were found to vary over
100-fold among these dG adducts, and the cis-adducts of dG
are repaired more rapidly than the trans-adducts [131]. It
waslaterfoundthatdiﬀerentconformationsof theseadducts8 Journal of Nucleic Acids
are recognized diﬀerentially by the NER lesion recognition
complex XPC-HR23B, which can be correlated with the rel-
atively low repair of (+)-trans-BPDE-N2-dG [121]. Similar
correlations were observed with UvrABC nuclease [134]. To
further show the importance of local DNA conformation,
the nature of the base opposite a BPDE adduct is found
to be critical in modulating the repair rates [38]. As will
be discussed below is Section 2.5, the processing of BPDE-
DNA adducts by both UvrABC and human NER is also
sequence dependent. BPDE forms N6-dA adducts in native
DNA as well, although relatively ineﬃciently [135, 136],
which exhibit diﬀerential conformation and perturbation of
DNA duplex than the BPDE-dG adducts [35]. Using cell
extracts, human NER activity has been shown for the (+)-
or (−)-trans-anti-BPDE-dA adducts [38, 131].
Several early studies showed that repair of BPDE-
DNA adducts occurs much faster in the transcribed strand
than in the nontranscribed strand of HPRT or p53 genes,
indicating that these adducts are subject to TCR [137, 138].
These adducts block human RNA pol II elongation on the
transcribed strand, which could be a signal for initiating
TCR, also in a stereochemistry- and sequence-dependent
manner [139]. A later work shows that common genetic
variations in Cockayne syndrome A (CSA) and B (CSB)
proteins are associated with NER repair capacity of BPDE-
induced DNA damage in smokers [140]. Mutations with
CSA and CSB result in Cockayne syndrome with impaired
TCR [64]. Taken together, this strand preference in repair
may contribute to the mutational property of the human
lung cancer p53 gene in response to BPDE exposure: repair
of BPDE adducts along the nontranscribed strand of p53 is
consistently slower than repair in the transcribed strand, and
repair at the major damage hotspots in the nontranscribed
strand is 2–4 times slower than repair at other damage sites
[138].
Dibenzo[a,l]pyrene (DB[a,l]P) is another PAH that has
been found to be present in tobacco smoke particulates and
is the most potent carcinogen of the PAHs tested to date
in rodent systems. Similar to the B[a]P-derived adducts, the
bulky adducts formed by (±)-anti-DBPDE possess diﬀerent
structures and adopt diﬀerent conformations [141]. They
are diﬀerentially repaired by NER in human cells with some
being poorly removed, as shown by a recent study [39]. The
repair of DBPDE-DNA adducts by NER has been shown to
be slower than the repair of BPDE-DNA adducts [142]. In
general, the poor repair by NER of DBPDE-DNA adducts, at
least some of them, may account for the high carcinogenicity
of the parent compound.
(2) Formation and Repair of DNA Adducts of Aromatic Amine
4-ABP. Chemicals in this class such as 4-ABP bind to DNA
bases mainly at C-8 position. Adducts can also be formed
at N2-a n dO6-o fd Ga n dN6-o fd A[ 30]. 4-ABP has been
established as a major human bladder carcinogen [143]. 4-
ABP forms DNA adducts after N-hydroxylation by P450
to the mutagenic metabolite N-hydroxy-4-aminobiphenyl
(N-OH-4-ABP). N-(deoxyguanosin-8-yl)-4-aminobiphenyl
(dG-C8-ABP) (Figure 2) is the major adduct of 4-ABP,
and the minor adduct is N-(deoxyadenosin-8-yl)-4-ami-
nobiphenyl (dA-C8-ABP) [144]. The major adduct has been
detected in the human cells after exposure to N-OH-4-ABP
[145]. This adduct was also identiﬁed from DNA of the
bladder biopsy samples from smokers and is quantitatively
related to smoking status [146]. dG-C8-ABP adducts have
been identiﬁed from human bladder cancer tissues [147,
148]. Moreover, higher levels of DNA adducts correlated
with more invasive tumors (higher tumor grades) [147]. The
unique binding pattern of 4-ABP in the p53 gene, that is, the
p53 mutational hotspots in bladder cancer at several codons
are also the preferential sites for 4-ABP adduct formation,
links 4-ABP to the etiology of bladder cancer [149].
Although the detailed molecular mechanism of the
repair of 4-ABP-DNA adducts is not clear, DNA fragments
modiﬁed with N-OH-4-ABP were shown to be incised by
E. coli NER complex, the UvrABC nuclease [150]. An early
study investigated the rate of disappearance of dG-C8-ABP
in human transitional cell carcinomas of the bladder and
showed that the majority of the adducts can be removed
within 48 hours after treatment with 4-ABP [151]. Another
study showed that dG-ABP was repaired rapidly while dA-
ABP persisted in human uroepithelial cells [144]. There is
evidence of the human NER pathway involvement in the
repair of these adducts, as the host cell reactivation (HCR)
assays performed in NER-deﬁcient cells showed reduced
repair of DNA lesions from plasmid treated with 4-ABP
[152]. In addition, it was shown that loss of function of the
p53 gene in human bladder epithelial cancer cells reduces
the eﬃciency of repair of dG-C8-ABP, suggesting that p53
may modulate its repair in target cells [151, 153]. The
relationship between deﬁcient DNA repair of 4-ABP-DNA
adducts and increased bladder cancer risk was supported
by the ﬁndings that such repair capacity was signiﬁcantly
lower in bladder cancer cases than in controls, and ever-
smokers with low DNA repair capacity exhibited a 6-fold
increased risk compared with never smokers with normal
repair capacity [152].
(3) Formation and Repair of Propano Adducts of α,β-
Unsaturated Aldehydes (Enals). Enals can arise from both
cigarette smoking and endogenous LPO [154]. Cigarette
smokecontainsrelativelyhighconcentrationsofacroleinand
crotonaldehyde. HNE is a unique product of ω-6 of PUFAs
[92].Acroleinisthesimplestenalandisamodelchemicalfor
this class of carcinogens. Acrolein is one of the most abun-
dant compounds in MSS (60–100μg/cigarette) and is also
present in SSS at high concentrations [5]. It is highly reac-
tive without metabolic activation. Acrolein forms exocyclic
adducts on DNA bases, predominantly 1,N2-dG adducts
[155, 156]. The principal adduct is γ-hydroxypropano-2 -
deoxyguanosine (γ-OH-PdG) that exists as a mixture of
C8-OH epimers (Figure 3)[ 157], and the other adduct
is α-hydroxypropano-2 -deoxyguanosine (α-OH-PdG). The
mutagenicity of α-OH-PdG is well established, while the
mutagenicity of γ-OH-PdG has been reported with mixed
results [158, 159] .B o t ha d d u c t sw e r er e c e n t l yf o u n di n
human lungs using LC-ESI-MS/MS [160]. Acrolein-DNA
adductshavebeendetectedinthetissuesofcigarettesmokers
with signiﬁcantly higher levels than those of nonsmokersJournal of Nucleic Acids 9
[161, 162]. Likewise, both crotonaldehyde and HNE also
form stereoisomeric propano dG adducts, and increased
crotonaldehyde-dG adduct levels were observed in smokers
[163]. HNE adducts have also been detected in rodent and
human tissues [163, 164]. The mutagenic potential of these
dG adducts were recently summarized by Minko et al. [157].
γ-HO-PdG is a substrate for E. coli UvrABC nuclease
[43, 165]. In humans, NER of this adduct has been reported
[158]. There is also biochemical evidence that the HNE-
DNA adducts are repaired by UvrABC [92] and mammalian
NER in cell-free extracts [92, 166]. A recent study revealed
that NER and recombination, but not MMR, are involved
in repair of HNE-treated phage DNA replicating in E. coli
[167]. Moreover, the repair rates were shown to be aﬀected
by the adduct stereochemistry when four HNE-dG isomers
weretested[166].Interestingly,althoughBERisabletoexcise
the 1,N2-εG adduct, it appears to have no in vitro activity
towards the structurally analogous adducts γ-OH-PdG, α-
OH-PdG, and PdG [168] and no in vivo protective role in
a mutagenesis assay based on the vector containing a γ-OH-
PdG [169].
Recentﬁndingsalsopointedtotheroleofhighlyaccurate
TLS in protecting cells from the potential genotoxicity of
the acrolein-DNA adducts [158, 165]. Previous in vivo site-
speciﬁc mutagenicity studies have shown an eﬃcient error-
free bypass of the γ-HO-PdG adduct [165, 170]. Work from
E. coli indicated that NER, recombination repair, and error-
free TLS are all involved in the cellular response to this major
acrolein-dG adduct [165].
(4) Formation and Repair of In Vivo HQ-/p-BQ-Induced
Hydroxyphenyl Adducts. Benzene is a well-established
human carcinogen and is associated with an increased risk
of leukemia [171]. It is a signiﬁcant volatile compound
in the vapor phase (12–48μg/cigarette) [5]. In one major
metabolic pathway, benzene is converted by P450 to benzene
oxide which is further converted to phenol, catechol (CAT)
and various derivatives [20, 172]( Figure 4). One biologically
important stable metabolite is p-BQ, an oxidation product
of HQ [20, 172]. A number of bulky DNA adducts have
been detected in vitro and in vivo when exposed to HQ
or p-BQ [95–98, 173–177]. Reaction of p-BQ or HQ with
DNA in vitro has been shown to result in the formation
of two ring exocyclic benzetheno adducts on dC, dA, and
dG [95–98]. These adducts are highly mutagenic as tested
in vitro with human pols involved in TLS and in yeast by
site-directed mutagenesis [178] .T h eB o d e l lg r o u ph a sf o u n d
that the DNA adducts formed in animals after benzene
administration are identical to those produced in cells
treated with HQ, suggesting that HQ is the main benzene
metabolite causing adduct formation in vivo [177]. By
32P-postlabeling, the principal DNA adduct caused by HQ or
p-BQ corresponds to N2-(4-hydroxyphenyl)-2 -dG(N2-4-
HOPh-dG) [173, 177]. Exocyclic adducts were also detected
in vitro from reactions of trans,trans-muconaldehyde
(MUC), a reactive ring-opened diene dialdehyde formed
from a minor metabolic route [179, 180]. It is still unclear
as to what role the above covalent DNA adducts may play in
benzene-induced carcinogenesis, since benzene also induces
other types of DNA damage as well as chromosomal damage.
For example, oxidized bases such as 8-oxoG can be caused
through the quinone/hydroquinone redox cycling [11]( a l s o
see Section 2.1). Benzene also generates DNA strand breaks
[181, 182] through direct attack by ROS or unstable DNA
adducts. As shown in Figure 4, catechol o-quinones can react
with DNA by 1,4-Michael addition to yield major N3A and
N7G adducts which are unstable and generate AP sites [183].
We recently reported the repair of N2-4-HOPh-dG E.coli
UvrABC nuclease [184]. The speciﬁcity of such repair was
also compared with those of DNA glycosylases and damage-
speciﬁc endonucleases of E. coli both of which were found
to have no detectable activity toward this adduct. We also
showed that p-BQ-modiﬁed plasmid is eﬃciently cleaved by
UvrABC, indicating the involvement of NER in repair of
benzene-derived DNA damage [184]. The role of NER in the
repairofHQ/p-BQ-inducedDNAdamagewasalsosuggested
in another mutagenesis study using HQ- or p-BQ-treated
plasmid containing the supF reporter gene in NER-deﬁcient
(XPA) human cells [185]. Note that HQ- and p-BQ-derived
exocyclic adducts are repaired by a diﬀerent mechanism
called nucleotide incision repair (NIR), as discussed below.
In general, although benzene metabolites show relatively low
DNA binding activity in vivo, their induced DNA damage
and repair seem to be complex [186].
2.3.2. Base Excision Repair (BER). BER is the primary repair
mechanism for the removal of small DNA lesions such as
alkylated, oxidized, and deaminated bases from endogenous
sources or environmental carcinogens [64, 187–191]. The
steps of the BER pathway have been well characterized [64]:
it is initiated by a damage-speciﬁc DNA glycosylase that
recognizesamodiﬁedbaseandcleavestheN-glycosylicbond
between the base and the sugar moiety. Glycosylases can
be divided into monofunctional, for example, alkylpurine-
DNA glycosylase (AAG, also MPG, APNG, and ANPG) and
thymine-DNA glycosylase (TDG), and bifunctional (with
an AP lyase activity), for example, OGG1, endonuclease III
homolog 1 (NTH1), and endonuclease VIII-like glycosylases
(NEILs). Each DNA glycosylase has its unique speciﬁcity,
but overlapping activities are common among various
DNA glycosylases that may have diﬀerent structures and/or
catalytic mechanisms [191]. After glycosylase, the resulting
AP site is processed by 5  AP endonuclease, AP lyase,
and DNA polymerase activities to cleave the AP site, trim
strand break intermediates, and catalyze repair synthesis.
A DNA ligase ﬁnally completes the process by sealing the
remaining nick. The basic BER mechanism described above
is complicated by the identiﬁcation of subpathways (i.e., the
short-patch and long-patch BER) in mammalian systems
[192]. There is also a network of protein-protein interactions
involving numerous proteins inside and outside of BER,
which is thought to play a key role in coordination of
B E Rc o m p o n e n t sa sw e l la si nr e g u l a t i o no fc e l l u l a rB E R
functions [193–195]. Evidence has emerged to support that
BER deﬁciency is an important contributing factor of cancer
susceptibility, as shown in both animal models and human
studies [196].10 Journal of Nucleic Acids
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Figure 4: Multiple benzene metabolites, diﬀerent types of DNA lesions, and proposed biological eﬀects. Benzene has a complex metabolism
and the listed metabolites are not a complete list. The adducts formed include those identiﬁed in vitro and in vivo, stable and unstable,
bulky and oxidized adducts. DSBs are one of the most severe DNA lesions caused directly and indirectly by benzene metabolites. Repair of
benzene-DNA adducts may include multiple mechanisms such as BER, NER, and NIR. Only those adducts that ﬁnally escape all the defense
mechanisms such as repair, or are misrepaired, may lead to mutations. Persistence or coexistence of diﬀerent types of lesions could form a
broad-based attack on the genomic stability. It is also known that a number of benzene metabolites can inhibit topoisomerase II (topo II)
activity, which may represent a potential mechanism for benzene’s clastogenic eﬀects [326].
Surveying the activities of known glycosylases indicates
that many of them are able to excise tobacco carcinogen-
induced DNA adducts, including the common alkylated and
oxidized bases and some exocyclic adducts. The tobacco
carcinogen-derived exocyclic DNA adducts listed in Figure 5
are known substrates for respective glycosylases as described
below. It should be noted that a crucial role of BER is
to repair an AP site which is mutagenic because of its
noncoding nature [197, 198]. As stated above, certain
tobacco carcinogens generate unstable DNA adducts that are
an important source of the AP sites in the genome.
(1)FormationandRepairofEthenoDNAAdducts. Etheno(ε)
adducts are the most extensively studied exocyclic adducts
[34, 199] which are formed by the attack of bifunctional
aldehydes or epoxides at a nitrogen of the base, followedJournal of Nucleic Acids 11
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Figure 5: Structures of smoking-induced bulky DNA adducts that are substrates for BER.
by dehydration and ring closure [34]. Cigarette smoke is a
signiﬁcant source for these adducts as shown by the urinary
levels of εC[ 200]a n d1 , N2-εG[ 201] in smokers. These
adducts could be formed by VC in cigarette smoke (5–
30ng/cigarette)aswellasLPOproducts[94].VCisprocessed
by P450 yield unstable chloroethylene oxide (CEO), which
quickly converts to chloroacetaldehyde (CAA) [202, 203].
Both CEO and CAA can form ε-adducts. In experimental
animals and in humans exposed to VC, liver angiosarcomas
are the most common type of tumors. CAA has been studied
extensively in terms of forming ε-adducts, [18, 99], and the
quantitative relationships in double-stranded DNA treated
with CAA are as follows: 3,N4-εC ≥ 1,N6-εA >N 2,3-εG ≫
1,N2-εG[ 204]. The mutagenic properties of these adducts
have been established [37], and there is evidence that ε-
adductsmayberesponsibleforras andp53mutations in liver
tumors of VC-exposed humans [33].
Studies on repair of exocyclic adducts have largely been
focused on BER, except for propano-dG adducts that are
repaired by NER. ε-Adducts are repaired by BER, initiated
m a i n l yb yt w oh u m a nD N Ag l y c o s y l a s e s :A A Ga n dT D G
[34]. In E. coli, they are repaired by functional homologs
of AAG and TDG: AlkA (m3A-DNA glycosylase II) and
mismatch uracil-DNA glycosylase (Mug), respectively [34].
Excision of εA. Human AAG excises this adduct from
double-stranded [205, 206] and single-stranded DNA [207].
ThecrystalstructureofhumanAAGboundtoDNAcontain-
ing an εA has been solved [208, 209]. AAG is also the major
activity against εA in vivo, as shown in Aag
−/− knockout
mice [210, 211]. Increased mutations were observed in the
hprt gene, and levels of εA were signiﬁcantly higher and
p e r s i s t e dl o n g e ri nD N Af r o mAag
−/− mice than those from
wild-type mice when treated with vinyl carbamate [210,
211]. Moreover εAa n dεC accumulated to higher levels in
Aag
−/− mice following stimulation of colonic inﬂammation,
indicating that the repair of such adducts formed by LPO
is important for protection against chronic inﬂammation-
induced ROS and carcinogenesis [212]. As described below,
the AlkB/ABH pathway is also involved in the repair of εA
and εC adducts. NER is not involved in its repair [213].
Excision of εC. We and Saparbaev et al. independently found
that the εC activity resides in both human TDG and E. coli
Mug proteins [214, 215]. The main biological role of TDG
appears to remove thymine from a T:G mismatch resulting
from the deamination of 5-methylcytosine (5-mC) in a CpG
site, which could be involved in active DNA demethylation
when in combination with a deaminase that converts 5-
mC to T leading to a T:G mismatch [216]. In vitro assays
have shown that the activity of TDG is most eﬃcient when
T:G or εC:G is in a CpG sequence context [217, 218].
Recently, the crystal structure of TDG (the catalytic domain)
complexed with DNA containing an AP site was reported
[219]. Other studies have also shown low excision of εC
by human single-strand-selective monofunctional uracil-
DNA glycosylase (SMUG1) [220] and methyl-CpG binding
domain protein (MBD4 or MED1) [221].
Excision of εG adducts. In rodents, N2,3-εG represents the
predominant ε-adduct and is readily induced in hepatic
nonparenchymal cells by VC, the target cells for this com-
pound [222]. There is a correlation between the levels of
this adduct and the incidence of VC-induced angiosarcoma
[222]. E. coli AlkA excises N2,3-εG from CAA-treated DNA
[223]. Both in vitro [224] and animal studies [222] showed
that the human removal of N2,3-εG is slow. It was also
shown that repair capacity would be diﬀerent in various12 Journal of Nucleic Acids
cell types in liver in that the expression of AAG mRNA was
induced in the hepatocytes of rat exposed to VC, while the
nonparenchymal cells had only 20% of the AAG mRNA of
hepatocytes, indicating that the target cells for VC had much
lower expression of this glycosylase [225]. It should be noted
that N2,3-εG is also an endogenous adduct arising from LPO
[225]. 1,N2-εG, an isomer of N2,3-εG, is a substrate for both
E. coli Mug and human AAG as tested in vitro [207, 226].
Excision of hydroxymethyl ε-adducts. We recently studied in
vitro repair of two exocyclic adducts formed by acrolein
metabolite glycidaldehyde (GDA), a potent mutagen and
animalcarcinogen.7-(Hydroxymethyl)-1,N6-ethenoadenine
(7-hm-εA), the main adduct, can be found in skin cells
of mice treated topically with GDA [227]. Minor adducts
with guanosine and deoxyguanosine were also found [228].
The 8-hm-εC adduct has only been identiﬁed in vitro [229].
These ε analogs are expected to be as promutagenic as the
corresponding ε-adducts, and 8-hm-εC has been shown to
miscode when tested with mammalian DNA pols [230].
Biochemical assays have shown that 7-hm-εA is primarily
repaired by AAG [231]. While 8-hm-εCi se x c i s e db yE.
coli Mug and human TDG [232], these excision activities
were from half-to a few-fold lower than the corresponding
ε activities, which could be attributed to the extra –CH2OH
group on the ε-ring [231].
2.3.3. Direct Reversal of DNA Damage
(1) Formation and Repair of Pyridyloxobutyl (POB)-DNA
Adducts of TSNAs. Tobacco-speciﬁc nitrosamines (TSNAs)
are exclusively found in cigarette smoke and are formed
throughN-nitrosationofnicotineduringtobaccocuringand
processing [233]. Common TSNAs found in cigarette smoke
particles include NNK, NNN, and N-nitrosoanatabine
(NAB). NNK has a strong aﬃnity for the lung and is a
systematic lung carcinogen [234]. NNK is among the most
potent lung cancer carcinogens in tobacco smoke [27].
TSNAs require activation by the P450 system [80]. In one
pathway, NNK is activated to form mutagenic O6-mG [235].
In addition, NNK- and NNN-generated reactive intermedi-
atesformbulkyPOB-DNAadducts,includingthe7-andO6-
positions of dG and the O2-position of dC and T [84]. Four
of them have been recently characterized and detected in
NNK- or NNN-treated animals [236]. One of them, O6-[4-
(3-pyridyl)-4-oxobut-1-yl]-2 -dG (O6-POB-dG) [237–239]
(Figure 2), will be discussed here, which has been shown to
be mutagenic in both E. coli and human cells using a site-
speciﬁc mutagenesis assay and is considered a critical lesion
in NNK/NNN carcinogenesis [240]. Higher levels of adducts
are found in lung and tracheobrunchial tissues of smokers
than in nonsmokers, by the detection of 4-hydroxy-1-(3-
pyridyl)-1-butanone (HPB), a product from acid hydrolysis
of the POB-DNA adducts [80]. Most recently, 1-(N-methyl-
N-nitrosamino)-1-(3-pyridinyl)-4-butanal(NNA)wasiden-
tiﬁed from thirdhand smoke (THS) as the major product
resulting from the reaction of nicotine with nitrous acid
(HONO),alongwithNNKandNNN[241](seeSection 3.2).
Both O6-mG and O6-POB-dG adducts have been shown
to be substrates for AGT [106, 237, 242]. However, the
repair of the bulky POB adducts has been much less
studied compared to O6-mG. AGT primarily repairs O6-
alkylguanine adducts and protects against mutagenicity of
respective alkylating agents [106]. It is not an enzyme but
an alkyl group acceptor. Repair occurs by transfer of the
alkyl group at the O6 position of G to a cysteine residue
at its active site of the protein, which results in a protein
conformational change that signals for its degradation [243].
AGT reaction is stoichiometric with O6-mG acting as a
suicide substrate; therefore, the cellular repair capacity is
limited by the constitutive levels of AGT that can be also
depleted under overdose of alkylating agents [106].
O6-POB-dG has been shown to be repaired by AGT
both in vitro [237]a n din vivo [244]. This adduct is
eﬃciently repaired by mammalian AGTs but poorly repaired
by bacterial counterparts, AdaC and Ogt [235, 244]. Since
both O6-mG and O6-POB-dG may have implications in
NNK-induced carcinogenesis, the relative repair rates of
these two adducts by AGT should be an important factor
in determining the levels and biological importance of these
two lesions. Studies by Mijal et al. [235] demonstrated that
human AGT showed an ∼2-fold preference for the removal
of O6-mG over O6-POB-dG, rodent AGTs exhibited the
same rate, and the bacterial proteins reacted poorly with
O6-POB-dG. These data indicate the high importance of
protein structure with respect to substrate eﬃciency. In
conclusion, AGT is expected to be critical in the repair
of O6-alkylguanine adducts formed by tobacco-derived N-
nitrosamines. It should be noted that cytotoxicity and
mutagenesis studies suggest an NER involvement in the
removal of NNK-derived DNA damage [236, 245]. A very
weak but time-dependent in vitro NER activity was also
detected using oligonucleotide containing an O6-POB-dG
and reconstituted human excision nuclease [236].
(2) Repair of Etheno Adducts by AlkB Homologs. It was
reported in 2005 that E. coli AlkB protein and its human
homolog, ABH3, repair εAa n dεC in vitro [246, 247]. Later,
ABH2 was shown to exhibit robust activity for εAa n d
is the principal dioxygenase for removal of εA in vivo as
shownbyAbh2
−/− mousestudies[248].Furtherexperiments
showed that ABH2, but not ABH3, is able to complement
the E. coli alkB mutant which is defective in the repair
of ε-adducts [248]. AlkB is a member of the superfam-
ily of iron-/α-ketoglutarate-dependent dioxygenases. Using
bioinformatics, eight mammalian homologs of AlkB, ABH1
to ABH8, have been identiﬁed [249]. The direct reversal
mechanism for their action involves a unique iron-mediated
reaction with cofactor α-ketoglutarate that could epoxidize
the exocyclic double bond of the ε-adducts [246, 247]. The
epoxide generated can be hydrolyzed to form the lesion-
free base and glyoxal. In addition to εAa n dεC, these
proteins also repair other methylated/ethylated bases [250,
251].Theycanactonbothsingle-anddouble-strandedDNA
substratesandmayplaydiﬀerent/complementaryrolestothe
glycosylases as mentioned above. In general, single-strandJournal of Nucleic Acids 13
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Figure 6: Structures of smoking-induced bulky DNA adducts that are substrates for NIR.
speciﬁcity suggests repair of lesions in single-stranded DNA
regions that are transiently generated during replication and
transcription.
Given that DNA glycosylases also act on ε-adducts (see
Section 2.3.2(1)), at least two repair pathways may act on
these adducts in vivo. This may explain why the incidences
of carcinomas were similar between wild-type and Aag-
knockout mice treated with vinyl carbamate [252]. Genetic
studies using AlkA-proﬁcient and -deﬁcient cells show that
AlkB is important for counteracting the mutagenicity of the
ε-adducts [246]. A study comparing the repair eﬃciency of
AlkB versus AlkA in E. coli shows that AlkA seems to be
the more important enzyme in response to exposure to CAA
[246].Similardatawereobtainedfromknockoutmice[248],
which showed that the Abh2 activity is not suﬃcient for the
removal of spontaneously produced εA adducts in Aag
−/−
mouseliver,whereasmouseAagactivityissuﬃcienttorepair
spontaneously produced εA lesions in Abh2
−/− mouse liver.
These results suggest that both AAG and ABH2/3 proteins
can play a role in the cellular response to the exposure of
tobacco carcinogens that generate these ε-adducts.
2.3.4. Nucleotide Incision Repair (NIR). The exocyclic ben-
zetheno p-BQ adducts are bulkier than the ε-adducts, with
an additional ﬁve-membered ring and a hydroxy group. As
might be expected, such bulky adducts hinder replication
in vitro and in vivo and cause frameshift deletions and base
mispairing [178]. In the past years, we have studied repair
of three major in vitro adducts formed by HQ and p-BQ
(designated as pBQ adducts), 1,N6-pBQ-dA, 3,N4-pBQ-dC,
and 1,N2-pBQ-dG (Figure 6). Our initial study discovered
that these adducts are recognized by the major human AP
endonuclease (APE1, also known as HAP1, APEX, and Ref-
1) as well as E. coli exonuclease III and endonuclease IV
[253, 254]. Mechanistic studies showed that human APE1
hydrolyzes the phosphodiester bond 5  next to the adduct,
leaving the p-BQ derivative on the 5 -terminal of the 3 
fragment as a “dangling base” [253, 255, 256]. This mode of
incision was later named nucleotide incision pathway [257,
258], which also acts on several oxidized DNA bases. While
theAPsiteisthepreferredsubstrateforAPE1,cleavageofthe
pBQ-dC adduct requires the same catalytic center as the AP
site as shown from mutant APE1 proteins [256]. Molecular
dynamics simulations [36] suggest that APE1 utilizes a
reaction mechanism for phosphodiester bond cleavage of
DNA containing pBQ-dC similar to that reported for the AP
site [259]. Given that these adducts have not been reported
to be present in vivo, the biological role of these adducts as
well their repair by NIR awaits further investigation.
2.3.5. Summary. The repair mechanisms for representative
bulky DNA adducts discussed above are summarized in
Figure 7. It should be emphasized that most of the repair
studies in the past have applied a single compound for
modiﬁcation or exposure, and results from such studies
cannot be simply extrapolated to real exposures. However,
theinformationonrepairspeciﬁcityandeﬃciencyfromsuch
studies provides the framework for further evaluation of
potential relationships among repair deﬁciencies, carcinogen
mutagenicity, and human susceptibility to cigarette smoke.
Also,asstatedabove,tobaccocarcinogensareabletogenerate
other speciﬁc DNA lesions in addition to bulky DNA
adducts. The importance of bulky DNA adducts relative
to other types of DNA lesions needs further investigation,
a n di na n yc a s e ,ac o m b i n e da c t i o nf r o md i ﬀerent types
of DNA/chromosomal damage, as demonstrated in Figure 4
f o rb e n z e n e ’b i o l o g i c a le ﬀects, is expected to be the basis of
genotoxicity conferred by many tobacco carcinogens.
2.4. Molecular Structure of DNA Adducts and DNA Repair. A
crucial question in repair is how repair proteins recognize
DNA adducts, since repair speciﬁcity has both biochemical
and biological implications. A related question is “what are
thefactorsresponsibleforgoodandpoorrepair?”Todate,we
have learned a great deal with regard to what structural fac-
tors of adducts and repair proteins determine the speciﬁcity
and rate of repair, mainly based on biochemical data atomic
resolution structures of adducted DNA and repair proteins
[64, 102, 260, 261].
The study of how a DNA adduct aﬀects the structure of
DNAandhowitinteractswithitsrepairproteinisessentialin
ordertodevelopatheoryforbothwhyonlysomeadductsare
repaired and the speciﬁc mode of repair. When surveying the
multiplicity of DNA substrates for NER, the primary repair14 Journal of Nucleic Acids
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pathway for many bulky DNA adducts, one basic question
is how NER recognizes these chemically diverse substrates
through the common structural features of the recognition
unit XPC-HR23B. Moreover, what is the basis for the fact
that the repair rates of diﬀerent bulky adducts by NER can
vary by several orders of magnitude [111, 262]? It should
be recognized that, as described above, the complexity of
these adducts is enormous, including those adducts that are
formed by compounds with stereochemical properties (e.g.,
BPDE, acrolein, and HNE). Recognition and repair rates of
such stereoisomeric adducts generally reﬂect or depend on
adduct conformation. In the case of BPDE-N2-dG adducts,
both their removal by human NER [131] and patterns of
helix opening by XPC-HR23B [121] are stereochemistry
dependent. Recently, crystal structures of NER proteins,
that is, bacterial UvrB [263] and yeast Rad4 (human XPC
homolog) [264], complexed with damaged DNA, have been
described, both of which suggest a mode of action involving
strand separation and nucleotide ﬂipping for the bulky DNA
lesions.
As for BER, a number of high-resolution structures of
glycosylases, including those complexed with DNA lesions,
have provided a valuable insight into adduct selection as well
as mechanisms of base ﬂipping and catalysis [260, 261, 265].
In addition, molecular modeling studies such as molecular
dynamics simulations have oﬀered additional information
about the structural features of DNA substrates and their
interactions with repair enzymes [36, 266]. Some common
features of recognition by DNA glycosylases can be summa-
rized based on the reported structural studies: (1) adduct
shape, hydrogen-bonding potential, and electric charge
distribution are key for recognition; (2) base unstacking is
present at the lesion site; (3) the target nucleotide has to be
ﬂipped out of the DNA duplex and ﬁt in the active site of
a glycosylase [261]. Similarly, AP endonucleases ﬂip an AP
site out into their active sites, as shown by the co-crystal
structures [259, 267]. Early on, we had some puzzling
questions for this pathway and its glycosylases. For example,
why are structurally related adducts repaired diﬀerentially?
for instance, BER excises the 5-membered unsaturated
exocyclic εG but not the 6-membered propano-dG [34, 157].
Also, why can lesions with largely diverse structures be
processed by the same protein, as seen by human APE1
acting on both AP site and pBQ-dC [253, 255, 256]? In
general, the key to the speciﬁcity of recognition has been
known to be not only the primary adduct structure, but
the localized eﬀect of each adduct on DNA structure as well
as on thermodynamics, and, moreover, the structure and
function of the repair protein. Since most repair enzymes act
on adducts in double-stranded DNA, each adduct may cause
diﬀering distortion and ﬂexibility as a result of factors such
as being in the major or minor groove, syn or anti, planar or
angular, adjacent base pair tilting, propeller twist, and helical
twist [102]. Ultimately, it is hoped that we can predict repair
speciﬁcity/eﬃciency as well as identify structural hallmarks
of mutagenic lesions in the genome, using appropriate
computational and/or screening approaches. This can only
be done after a large amount of structural and theoretical
data have been acquired, which relate adduct structural
features with outcomes of repair and mutagenesis.
2.5. Nucleic Acid Sequence, Mutational Hotspots, and DNA
Repair. The sequence-dependent repair infers that local
DNA structures adjacent to an adduced nucleotide are
important determinants of repair speciﬁcity and eﬃciency.
The study of the role of sequence in base modiﬁcation was
started mainly in the 1980s in terms of sequence selectivity
for mutational events which were generally induced by
environmental agents [268]. Extensive work on relating
sequence-dependent adduct formation and mutation hasJournal of Nucleic Acids 15
been done using chemical modiﬁcation (e.g., BPDE) of
genomic DNA, followed by determination of the mutation
pattern and spectra [268] .T h e s ed a t aw e r ea m o n gt h e
ﬁrst used to substantiate the concept of “hotspots”; that
is, for a given reagent, there was site speciﬁcity for DNA
modiﬁcation. An example is that in vivo, only the second
guanine residue in codon 12 (GGA) of the H-ras gene
was modiﬁed by an alkylating agent, leading to G:C to
A:T mutations [269], which is consistent with other studies
demonstrating the sequence-dependent formation of O6-
alkylguanine in DNA [270, 271].
In addition to preferential DNA adduct formation at
speciﬁc sites, poor repair is another major determinant of
mutational hotspots [30]. Many studies have highlighted
the importance of sequence context in inﬂuencing the rate
and extent of repair [268]. Examples among the tobacco
carcinogen-induced bulky DNA adducts are BPDE-DNA
adducts [134, 138, 272–274], POB-DNA adducts [242], εA
[275], and εC[ 232], whose repair eﬃciencies could vary
overmanyfoldwhenpresentindiﬀerentneighborsequences.
These examples involve repair systems including at least
N E R ,B E R ,N I R ,a n dA G T[ 268]. A review by Singer and
Hang commented on many enzymes in these pathways with
regard to the role of adduct, neighbor bases, and repair
rate [268]. Also, Donigan and Sweasy recently summarized
the known sequence context-speciﬁc activities of several
glycosylases and polymerase β in BER [276]. It can be
concluded now that sequence-dependent repair tends to be
predominant, instead of being a random phenomenon.
Mechanistically, the structural factors that modulate
sequence-dependent repair have been well studied with
certain adducts such as BPDE-DNA adducts [274, 277].
An NMR study using a sequence containing a natural GG
mutational hotspot showed that the presence of the major
BPDE-derived dG adduct at one of the two neighboring G
positions resulted in signiﬁcantly diﬀerent local structural
distortions, especially bending or kinking at the adduct posi-
tion and destabilization of Watson-Crick hydrogen bonding
of the ﬂanking base pairs [35]. Using the same sequences,
Kropachev et al. demonstrated that such hydrogen bonding
destabilization elicits the most signiﬁcant NER response,
while the ﬂexible kink is less important in such interaction
[274]. It is also apparent that the chemical nature of a DNA
adduct itself can aﬀect the eﬀect of neighbor sequences. For
example,therepairofaPOBadductbyAGTismorestrongly
inﬂuenced by its neighbor bases than that of the smaller
methylated base substrate [242].
Regardless of the nature of the speciﬁc structural dif-
ferences discussed above, current evidence also supports
that thermodynamic stability of lesion-containing oligonu-
cleotides plays an important role in sequence-dependent
repair[268,274,278].InthecaseofBPDE-DNAadducts,the
degree of local thermodynamic destabilization was related to
the degree of recognition of duplex sequences containing a
bulky adduct by the NER machinery [262, 274, 279]. Both of
our studies on sequence-dependent repair of εA[ 275]a n d
AP site [280] also demonstrated a role of thermodynamic
properties in inﬂuencing double-strandedness of the sub-
strates and repair their eﬃciency.
Recent studies have discovered a strong coincidence of
mutational hotspots in human lung cancers and the sites
of preferential binding of BPDE [42, 281] and acrolein [43]
in the p53 gene. The overall prevalence of p53 mutations is
higher in cigarette smokers than in nonsmokers [51, 52].
A number of hotspots have been found along p53 in lung
cancer which are generally G to T transversions [30]. It
has been reported that in PAH- or acrolein-treated cells the
same positions of their mutation hotspots are also major
hotspots for mutations observed in human lung cancers
from smokers, strongly suggesting a role of DNA adducts in
etiology of these cancers [30]. As discussed above, poor/slow
repair of DNA adducts at these sites may be a major factor
for their occurrence and persistence at these mutational
hotspots. To further support this nation several groups in
the mid-1990s examined the in vivo repair rates along a
gene fragment using the ligation-mediated PCR technique
[282]. As for BPDE adducts in human HPRT and p53
genes, Wei et al. [272] found that repair rates can diﬀer
markedly from site to site over a time period, as measured
by the percentage of adduct remaining. Moreover, very slow
repair was observed at certain positions that are frequently
mutated after BPDE treatment [272] .T h e s es t u d i e sc l e a r l y
indicateacorrelationbetweenineﬃcientDNArepairandthe
occurrence of mutation hotspots. Finally, in addition to site-
speciﬁcpreferentialformationofDNAadductsandsequence
context of DNA repair, the biological selection of induced
mutations is also considered important for the hotspot
phenomenon, which gives cells with speciﬁc mutation(s)
a growth advantage and results in dominant mutations in
cancer cells [283, 284].
2.6. Interindividual Variations in Response to Tobacco Car-
cinogens and Cancer Risk. It has long been recognized that
only a small percent of cigarette smokers develop cancer,
for example, ∼11%–24% of smokers develop lung cancer
[285], which suggested that interindividual variability in key
cellular processes is crucial in response to tobacco carcino-
gens. Many molecular and epidemiological studies have been
revealing a multifactorial nature of such variability [286–
289]. One top aim of the target cancer prevention programs
is to identify smokers and nonsmokers exposed to SHS
with higher susceptibility. The interindividual diﬀerences
discussed below will be focused on those genotypes and
phenotypesinvolvingDNArepaircapacity(DRC)inrelation
to the mutagenicity and carcinogenicity of tobacco-induced
bulky adducts.
Considerable progress has been made towards a bet-
ter understanding of the association between individual
tobacco carcinogens and tumor development in speciﬁc
organs/tissues [12], as exempliﬁed by the following cases:
NNK and PAH are potent lung carcinogens; aromatic
amines such as 4-ABP are the main cause of bladder cancer
in smokers; benzene induces acute myelogenous leukemia
(AML). Whether reduced or deﬁcient DRC for tobacco
carcinogen-derived DNA damage is associated with somatic
mutation and susceptibility to cancer has been a subject
of investigation. A commonly used approach is to measure
the repair or levels of speciﬁc DNA adducts which serve as16 Journal of Nucleic Acids
an intermediate end-point of genotoxicity [14]. Decreased
repair activities for bulky DNA adducts have been observed
incells/tissuesofcancerpatients.Forexample,epidemiologic
studies using the HCR assay showed that low cellular DRC in
response to BPDE-induced DNA damage is associated with
increased risk of lung, head, and neck cancers [65, 286, 290].
Biochemical studies also showed that reduced repair of εA
and εC adducts was present in lung adenocarcinomas [291].
In principle, the phenotypes of DNA repair must be char-
acterized for mutagenic adducts and any newly identiﬁed
adducts in smokers and nonsmokers exposed to SHS.
Deﬁcient repair towards tobacco smoking-related DNA
adducts may occur under various mechanisms. A common
one is polymorphisms in relevant DNA repair genes, such
as those identiﬁed in the NER, BER, and AGT pathways
[289, 292, 293]. It has been shown that cellular levels of
DNA adducts such as those arising from BPDE exposure can
be aﬀected in some of those genetic variants [132, 294]. In
the last decade, although mixed or discrepant results have
been reported, positive results on numerous polymorphisms
in DNA repair genes, along with those in metabolic genes,
have been revealed and are continuously being found in the
context of cigarette smoking and cancer [22, 295, 296]. It
seems that polymorphisms in tobacco metabolism and/or
repair should lead to diﬀerences in both local carcinogen
levels and/or DNA adduct levels in vivo [14]. Another
mechanism that can cause the loss of DNA repair capacity
is LOH; for instance, LOH at the human 8-oxoG-DNA
glycosylase (OGG1) gene locus is a frequent event in lung
cancer, which would increase the mutational load from 8-
oxoG due to ROS in smokers [297].
DRC could also be inﬂuenced by nongenetic factors that
cause a phenotypic reduction/ablation of repair activities.
Examples of such factors include those that are disease
related, for example, NER deﬁciency in XP and Cockayne
syndrome patients [64, 140], and those that are repair-
inhibition based. For the latter, carcinogen-mediated eﬀects
on proteins play an important role. Two types of tobacco
chemicalscancauseproteindamageandinhibitrepair.There
are at least 30 metals in cigarette smoke, including arsenic,
cadmium, nickel, and chromium, which have been shown
to inhibit various DNA repair enzymes and pathways [298–
302]. For instance, both arsenic and nickel compounds
interfere with the repair of BPDE-DNA adducts [298, 299].
Cadmium and chromium (VI) are also known as eﬀective
DNA repair inhibitors and play a similar role in inﬂuencing
adduct levels in smokers [303, 304]. Therefore, coexposure
totheseheavymetalsbysmokersmayenhancethemutagenic
potentialofgenotoxictobaccocarcinogens[305].Inaddition
to metals, certain tobacco carcinogens themselves have been
found to inhibit DNA repair, as exempliﬁed by acrolein
inhibitingNERrepairofBPDE-DNAadducts[43].Similarto
metals, the coexistence of these chemicals in cigarette smoke
is also expected to lead to more persistent or severe DNA
damage as a result of suppressed DNA repair.
In addition to tissue diﬀerences in bioactivation of
tobacco carcinogens [306, 307], recent studies in rodents
suggest that the DRC in a given organ/tissue/cell type may
play a role in organoselectivity of tobacco carcinogens.
For example, both AGT [308] and NER [309] activities
are related to the interorgan diﬀerences in response to
NNK treatment, which could be an important factor in
determining organ-speciﬁc susceptibility to NNK-induced
carcinogenesis. Another example is benzene which targets
the bone marrow. DNA adduct levels in the bone marrow
of benzene-treated mice are signiﬁcantly higher than those
in liver, as shown by tissue distribution studies [310].
Interestingly, although no repair capacity has been tested
for a particular benzene adduct in vivo, when treated with
alkylating agents, the DRC of primary human hematopoietic
CD34+ cells from bone marrow was signiﬁcantly lower than
more diﬀerentiated CD34
− cells of the same donor [311]. In
general, the tissue- or cell type-speciﬁc responses to tobacco
exposure and their mechanisms are not well understood and
await more extensive investigation.
3. From the Known to the Unknown:
FutureandPerspective
3.1. Uncharacterized Adducts and Repair. The bulky DNA
adducts discussed here are only a small list of represen-
tatives derived from tobacco carcinogens. We need not
only more information on these important bulky adducts,
but also more knowledge of those other adducts that are
still not understood. (1) There are many other chemicals
in cigarette smoke that have not yet been evaluated for
DNA adduct-forming ability. For instance, there are 18 N-
nitrosamines and 106 aldehydes present in cigarette smoke
[10]. (2) Chemicals may be neglected only because of their
lower concentrations in cigarette smoke. For example, some
PAHs exist in cigarette smoke at low amounts relative to
B[a]P. Some of these compounds may even have stronger
carcinogenic eﬀect [30]. (3) The research attention tends
to be more focused on the eﬀect of the major adducts of
a chemical carcinogen. However, in some cases, the minor
adducts are substantially more mutagenic than the major
ones.Forexample,thebiologicalresponseofN-nitrosamines
could be correlated with minor forms of DNA damage
[312]. However, the repair speciﬁcity and kinetics of these
DNA lesions are still unknown. (4) Many bulky adducts
have been identiﬁed in vitro under physiological conditions
but have not been detected yet in vivo. Examples include a
number of exocyclic adducts formed by benzene metabolites
(Figure 4). Although many in vitro s t u d i e sh a v eb e e nf o c u s e d
on the HQ- and p-BQ-derived benzetheno adducts [313]
and MUC-DNA adducts [179], no conclusion can yet be
drawn on whether they are formed in cells/tissues. (5)
In some cases, bulky DNA adducts are detected from the
tissuesofexposedhumansoranimalsusing 32P-postlabeling,
but their chemical structures have not been elucidated.
These adducts were generally described in the litrature as
“aromatic or hydrophobic adducts”. (6) Endogenous DNA
adducts can be formed as a result of cigarette smoke, which
is currently attributed to the formation of LPO products
[92–94]. Further research is needed to learn the dose-
response relationship with regard to the formation of these
adducts as well as their relative importance in smoking-
induced carcinogenesis. The complexity of such analysisJournal of Nucleic Acids 17
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is that the same DNA adducts, for example, the ε-DNA
adducts, are generated by both tobacco carcinogens and
endogenously formed compounds, even though they can
be chemically diﬀerent [49]. (7) Although the majority
of studies on adducts and cancer have focused on stable
ones, many adducts formed by tobacco carcinogens are
chemically unstable, for example, the benzene-derived CAT-
4-N3A and CAT-4-N7G [183], and the potential eﬀects of
such adducts versus stable adducts are largely unknown. (8)
ManyDNAadductshavebeendetected,someincells/tissues,
but not yet characterized with respect to their repair. An
example is that the epoxides of 1,3-butadiene [314, 315],
a tobacco carcinogen in both MSS and SSS, cause the
formation of N-1-(2,3,4-trihydroxybutyl) adenine adduct
in human samples [316], but its repair is unknown. (9)
Sometimes cellular repair has been detected using repair-
deﬁcient cells/animals in combination with mutagenesis
assays, but detailed biochemical properties of such repair
have not been elucidated. In other cases, repair studies have
only been performed in vitro, such as the p-BQ-derived
benzetheno adducts [253, 255]. Although animal studies
have limitations with signiﬁcant diﬀerences from humans,
many important experiments on the formation and repair of
carcinogenic adducts can only be performed in appropriate
animals.Themajordiﬀerenceisthatinvivo,enzymesma ybe
inducible and become saturated at the carcinogen dose used,
and in the genome, there can be preferential repair as well as
organand cellvariations and there maybe cooperative repair
mechanisms which have not been well understood. This is
only a partial list of the reasons why repair speciﬁcity and
eﬃciency discovered in vitro have to be validated in vivo.
3.2. SHS and THS Carcinogens and DNA Adducts. To inves-
tigate the relationship between cigarette smoking and DNA
damage, understanding of the chemical and biophysical
properties of various forms of tobacco smoke is also critical.
For instance, although a great deal is known about the
chemistry and toxicity of MSS and SHS, little is known
about the identity and molecular toxicology of toxicants
produced de novo in THS [6, 7]. However, it has been well
established that indoor surfaces signiﬁcantly adsorb semi-
and nonvolatile SHS compounds, for example, nicotine, 3-
ethenylpyridine, naphthalene, cresols, and phenol which are
slowly reemitted into the air [317–320]. Therefore, all of
these compounds can be signiﬁcant components in THS.
Moreover, compounds sorbed onto a surface can undergo
chemical transformations by reacting with common reactive
atmospheric species. Recent indoor chemistry studies have
elegantly revealed that nicotine reacts with ozone (O3)t o
yield aldehydes and possibly myosmine [317]a n dw i t h
nitrous acid (HONO) to form NNA, NNN, and NNK [241]
(Figure 8). NNA was identiﬁed as the major product, which
is absent in freshly emitted tobacco smoke but found in
in vitro reaction of nicotine with NaNO2 [321]. NNA has
a mutagenic activity similar to that of NNN [322], but its
tumorigenic activity in animals was not conclusive [323,
324]. So far, nothing has been tested for its potential to form
D N Aa d d u c t s ,b u ti ti se x p e c t e dt ob er e a c t i v ew i t hD N A
due to its aldehyde group. Therefore, it would be important
to assess its intake and biological properties. Based on their
chemical structure, all of the by-products shown in Figure 8
are anticipated or have already been known to form DNA
adducts.18 Journal of Nucleic Acids
As stated earlier, SSS and SHS, the precursors of THS,
contain thousands of chemicals, including nicotine and
well-deﬁned carcinogens, partitioned between the gas and
particulate phases. The secondary analysis by Schick’s group
of animal experimental data from the past documents of
Philip Morris available at University of California, San
Francisco (UCSF) concluded that the mature and “aged”
SSS is several-folds more toxic than the fresh SSS [325].
Suchevidenceconstitutescompellingandsuﬃcientrationale
to determine the chemical composition of unique toxicants
produced in THS de novo and to detect new/diﬀerent types
of DNA adducts formed by “aged” SSS. In conclusion, this is
a new and important research area with regard to developing
strategies and methods to identify the chemical components
SHS aging and THS and to assess currently unknown
genotoxic potential and biomarker availability through DNA
adduct studies.
3.3. Future Directions. Understanding the mechanisms of
formation and repair of bulky DNA adducts is critical for
analysis and management of tobacco-induced mutagenesis
and carcinogenesis. It is hoped that continued studies
will provide more information about the structural and
biological implications of speciﬁc bulky DNA adducts and
the broader range of their eﬀects during the pathogenesis.
Future eﬀorts should be made to identify and characterize
novel compounds and adducts, such as those produced in
aged SHS and THS, to identify those highly mutagenic
adducts that are refractory to DNA repair, to ﬁnd adducts
as reliable biomarkers for measuring exposure, especially for
SHS and THS, to explore new potential biological functions
of adducts, such as their interactions with cellular signaling
networks, impact on stem cells of target tissues, and roles in
epigenetic changes, and to ﬁnd eﬀective ways to inhibit DNA
adduct formation in target organs. Innovative study designs
along with more comprehensive approaches (e.g., systems
biology) and new technology development (e.g., high-
throughput analysis) will be important for achieving these
goals. Ultimately, a better knowledge of the mechanisms by
whichthechemicalcarcinogenexposureincreasescancerrisk
in smokers and individuals exposed to SHS/THS could lead
to new strategies for cancer prevention and could serve as
theexperimentalevidenceforframingandenforcingtobacco
control policies in order to minimize health hazards and
protect vulnerable populations.
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